Vaccine for HER2 breast cancer shows early promise

March 13, 2019 10:49 AM | Deleted user

March 13, 2019, Duke Cancer Institute  

A vaccine developed by Duke Cancer Institute researchers has shown early promise in targeting the HER2 protein that fuels a deadly form of breast cancer. In a phase 1 clinical trial that enrolled 22 women with recurrent cancers that over express the HER2 protein, the vaccine demonstrated an ability to halt tumor growth, and improve survival for a subset of patients. A phase 2 trial is being planned at Duke. 

Read more.

Powered by Wild Apricot Membership Software